Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

This study has been completed.
Information provided by:
Kissei Pharmaceutical Co., Ltd. Identifier:
First received: September 20, 2012
Last updated: May 29, 2014
Last verified: May 2014
The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

Condition Intervention Phase
Dry Eye Syndromes
Drug: KCT-0809
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Resource links provided by NLM:

Further study details as provided by Kissei Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Score of the Corneal conjunctival staining [ Designated as safety issue: No ]

Arms Assigned Interventions
Experimental: KCT-0809 ophtalmic solution Drug: KCT-0809
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Corneal and conjunctival damage
  • Insufficiency of lacrimal secretion
  • Ocular symptom

Exclusion Criteria:

  • Severe ophthalmic disorder
  • Punctual plugs or surgery for occlusion of the lacrimal puncta
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01692145

Tokyo and Other Japanese City, Japan
Sponsors and Collaborators
Kissei Pharmaceutical Co., Ltd.
  More Information Identifier: NCT01692145     History of Changes
Other Study ID Numbers: KCT1204 
Study First Received: September 20, 2012
Last Updated: May 29, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Kissei Pharmaceutical Co., Ltd.:
Dry eye syndromes
Corneal diseases
Conjunctival diseases

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Pathologic Processes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases processed this record on October 21, 2016